Don't Miss this Key Inflation Report ⚠

The Nasdaq led US benchmarks higher on Thursday with a 0.7% gain. The S&P 500 advanced 0.5%, and the Dow added 0.4%. However, the small-cap Russell 2K slid to a 0.1% loss on the session.

Today, futures are ticking higher in early morning trading. Dow and S&P 500 contracts are up 0.1%.

Analysts Say This Stock Could Explode 💥

Analysts from three different research firms are raging about this up-and-coming biotech firm.

Even better, one of the company's most promising drug candidate could be on pace for a regulatory approval, which has potential to skyrocket share prices.'

Wall Street's price targets on the stock call for a potential upside of more than 300% from its current price point.

Now could be the perfect time to build up a position in this promising biotech stock.

Get the Stock's Ticker Symbol & a Full Report Here

💸 Euro Inflation Sets New Record.

Core inflation in the European Union hit 5.7% in March, setting a new record for the 20-member economic bloc and ticking higher from the previous month's 5.6% figure.

The hotter-than-expected read reduces the chance that the European Central Bank will pause its rate hike schedule in the foreseeable future.

Digital World Acquisition Corp is up on news of the former president's indictment.

A New York grand jury indicted the former president yesterday for falsifying business records, and the news is giving his SPAC a boost.

DWAC has a deal in place to bring Trump-backed social media platform TRUTH Social public, so the stock is reacting to news of the indictment.

No news has come out relating to TRUTH Social or DWAC, but the stock is nonetheless leading today's premarket gainers.

DWAC is one of this morning's top movers with a 11.4% gain in early premarket trading. Additionally, DWAC warrants (DWACW) are up by a whopping 45.1%

My Take: DWAC often behaves like a Trump sentiment gauge, and I think that's what we're seeing here. Alternatively, investors may believe the indictment could drive more users to sign up for TRUTH Social. Either way, the indictment has definitely put DWAC at center stage for the moment.

Rumble [RUM] - Last Close: $9.34

Rumble is moving higher after an earnings beat.

The alternative video sharing platform released it Q4 results late Thursday, and the numbers beat analysts' expectations.

Rumble reported break-even EPS for the quarter, beating the consensus estimate of a $(0.02) per share loss.

Revenues of $20 million were up substantially from $2.9 million in the year-earlier quarter, and they beat the Street's $10.2 million target by a wide margin.

Rumble also said its global monthly active users reached 80 million in Q4, up 142% year-over-year.

Shares of RUM are up 13.7% in the premarket, and RUMW warrants are up a whopping 30.2%.

My Take: RUM is putting up fantastic growth figures, but the company is still small and battling for market share. News of President Trump's indictment could also be giving this stock a boost, as it is widely viewed as a "conservative friendly" alternative to Alphabet Inc's [GOOG] YouTube.

Palisade Bio [PALI] - Last Close: $2.65

Palisade is running hot on the heels of a bullish analyst note.

Yesterday morning, Maxim Group analyst Naz Rahman upgraded the clinical-stage biotech firm from "Hold" to "Buy" and announced a $50 price target.

The analyst upgrade rallied shares of Palisade Bio on Thursday. The stock closed the session with a 57.7% gain.

However, the rally didn't stop at the closing bell, and shares continued to push higher in Thursday's after-market.

This morning, shares are up 35.8% in premarket trading, and it's one of the premarket's most active stocks.

My Take: This rally is starting to look like it's overdone. After all, an analyst note has zero material impact on a company's business. I expect we'll she a pullback in shares of PALI at some point.

Inpixon is rallying after reporting its full-year financial results.

The IT services firm released its fiscal 2022 earnings report after Thursday's closing bell, and investors were very pleased with the results.

Inpixon's annual revenues came in at $19.4 million, marking a 21% increase from the previous year's total.

The company also reported a non-GAAP loss of $(12.25) per share. Although steep, it was a significant improvement from last year's $(18.77) per share loss.

CEO Nadir Ali also commented that a recent spin-off of the company's workplace experience products was a "significant accomplishment... for the benefit of our shareholders."

INPX is one of this morning's top stocks with a 25.9% gain on active trading volume.

My Take: INPX posted impressive revenue growth, but their loss seems steep. Companies that can't turn a profit have potential to perform poorly during times of uncertainty, so I recommend you think twice before betting the barn on this stock.

I-Mab Dr [IMAB] ... AM
Fathom Digital Manufacturing Corporation [FATH] ... AM
Creative Media & Community Trust Corporation Reit [CMCT] ... AM
Advent Technologies Holdings, Inc. [ADN] ... AM
Msp Recovery, Inc. [LIFW] ... PM
Virtra, Inc. [VTSI] ... PM
Miromatrix Medical Inc. [MIRO] ... PM
Strata Skin Sciences, Inc. [SSKN] ... PM
Williams Industrial Services Group Inc. [WLMS] ... PM
Inhibikase Therapeutics, Inc. [IKT] ... PM